Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CALSEA BONE is a multi-ingredient dietary supplement developed by Fremed Pharmaceutical Joint Stock Company in Vietnam. Formulated as a hard capsule, it contains a synergistic blend of calcium and magnesium derived from ocean algae (Algaecal®), supplemented with Vitamin D3, Vitamin C, and Vitamin K2. The product is intended to support bone mineral density and reduce the risk of calcium deficiency and osteoporosis, particularly in adults and the elderly. Vitamin D3 enhances intestinal calcium absorption, while Vitamin K2 (as menaquinone-7) facilitates the incorporation of calcium into the bone matrix by activating osteocalcin. Vitamin C is included to support collagen synthesis, which provides the structural framework for bone mineralization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CALSEA BONE.